M. Wattad

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

N. Schmitz, M. Stauch, Y. Ko, 2020, Leukemia.

Optimal CD34(+) cell dose in autologous peripheral-blood stem-cell transplantation.

O. Sezer, K. Possinger, B. Metzner, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity. A randomized clinical trial

N. Halama, L. Bullinger, M. Addo, 2022, medRxiv.

S282: A RANDOMIZED CONTROLLED CLINICAL TRIAL DEMONSTRATES THAT PLASMA FROM CONVALESCENT AND VACCINATED DONORS IMPROVES OUTCOME OF COVID-19 IN PATIENTS WITH HEMATOLOGICAL DISEASE, CANCER OR IMMUNOSUPPRESSION

N. Halama, R. Schlenk, F. Herth, 2022, HemaSphere.

Clinical and genetic characterization of de novo double-hit B cell precursor leukemia/lymphoma

C. Haferlach, H. Serve, Sebastian E. Koschade, 2019, Annals of Hematology.